Related Experiment Videos
Selective 5-lipoxygenase inhibition in ulcerative colitis
L S Laursen1, J Naesdal, K Bukhave
1Department of Medical Gastroenterology, Odense University Hospital, Denmark.
Lancet (London, England)
|March 24, 1990
Summary
This study found that the 5-lipoxygenase inhibitor A-64077 significantly reduced leukotriene B4 (LTB4) levels in ulcerative colitis patients. Prostaglandin E2 (PGE2) levels remained unchanged, suggesting LTB4
Area of Science:
- Gastroenterology
- Inflammation Research
- Pharmacology
Background:
- Ulcerative colitis (UC) is associated with increased levels of inflammatory mediators.
- Leukotriene B4 (LTB4) and prostaglandin E2 (PGE2) are key eicosanoids implicated in inflammatory processes.
Purpose of the Study:
- To investigate the effect of the 5-lipoxygenase inhibitor A-64077 on LTB4 and PGE2 concentrations in patients with active ulcerative colitis.
- To assess the role of 5-lipoxygenase products in the inflammatory response of UC.
Main Methods:
- Ten patients with active ulcerative colitis were enrolled.
- Rectal dialysis fluid was collected before and at various time points after oral administration of 800 mg A-64077.
- Concentrations of LTB4 and PGE2 were measured using established assays.
Main Results:
- A significant reduction in median LTB4 levels was observed post-treatment, decreasing from 4.9 ng/ml to 1.6 ng/ml at 4 hours and 0.7 ng/ml at 8 hours.
- LTB4 levels returned to baseline by 28 hours.
- No significant change in PGE2 concentration was detected.
Conclusions:
- The 5-lipoxygenase pathway, producing LTB4, plays a significant role in amplifying the inflammatory response in ulcerative colitis.
- A-64077 effectively inhibits LTB4 generation in vivo.
- Further controlled clinical trials are warranted to evaluate the therapeutic efficacy of A-64077 for ulcerative colitis.